Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00678015 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00678015 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 12 participants.
The verdict
NCT00678015, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase II, single center study measuring the pharmacokinetic parameters of NDGA administration and assessing the proportion of patients who experience a 50% decline in PSA.
Interventions
- DRUG Nordihydroguaiaretic Acid (NDGA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00678015
The ClinicalTrials.gov registry entry for NCT00678015 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nordihydroguaiaretic Acid (NDGA) is the first listed.
NCT00678015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00678015 about?
NCT00678015 is a clinical study titled "Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non Metastatic Recurrent Prostate Cancer". This is a Phase II, single center study measuring the pharmacokinetic parameters of NDGA administration and assessing the proportion of patients who experience a 50% decline in PSA.
What is the current status of trial NCT00678015?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2008-05. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00678015?
The interventions under investigation include: Nordihydroguaiaretic Acid (NDGA) (DRUG).
Who is sponsoring clinical trial NCT00678015?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.